Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The largest, most extensive global network study on background rates for adverse events of special interest identifies important age, sex and database differences that should inform future safety surveillance efforts.

Vials of the Covid-19 vaccine

COVID vaccine surveillance efforts are a global priority, but safety monitoring for vaccines should not reflect a single global population. The largest international network study ever completed on the background rates of adverse events of special interest (AESI) being monitored in vaccine surveillance efforts identified that these rates vary substantially by age, sex, and database.

Led by researchers at the University of Oxford, Columbia University, Erasmus MC, UCLA, and Janssen, an international team of collaborators within the Observational Health Data Sciences and Informatics (OHDSI) network provided a timely reference of the background rates of AESIs in the recent study "Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study" published by The BMJ

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website